These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
309 related articles for article (PubMed ID: 29712428)
1. NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer. Zhang K; Chen D; Ma K; Wu X; Hao H; Jiang S J Med Chem; 2018 Aug; 61(16):6983-7003. PubMed ID: 29712428 [TBL] [Abstract][Full Text] [Related]
2. Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential. Colucci MA; Moody CJ; Couch GD Org Biomol Chem; 2008 Feb; 6(4):637-56. PubMed ID: 18264564 [TBL] [Abstract][Full Text] [Related]
3. Implications of NQO1 in cancer therapy. Oh ET; Park HJ BMB Rep; 2015 Nov; 48(11):609-17. PubMed ID: 26424559 [TBL] [Abstract][Full Text] [Related]
4. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones. Winski SL; Swann E; Hargreaves RH; Dehn DL; Butler J; Moody CJ; Ross D Biochem Pharmacol; 2001 Jun; 61(12):1509-16. PubMed ID: 11377380 [TBL] [Abstract][Full Text] [Related]
5. 2-Substituted 3-methylnaphtho[1,2-b]furan-4,5-diones as novel L-shaped ortho-quinone substrates for NAD(P)H:quinone oxidoreductase (NQO1). Bian J; Deng B; Xu L; Xu X; Wang N; Hu T; Yao Z; Du J; Yang L; Lei Y; Li X; Sun H; Zhang X; You Q Eur J Med Chem; 2014 Jul; 82():56-67. PubMed ID: 24874653 [TBL] [Abstract][Full Text] [Related]
6. Research advances in NQO1-responsive prodrugs and nanocarriers for cancer treatment. Yang X; Duan J; Wu L Future Med Chem; 2022 Mar; 14(5):363-383. PubMed ID: 35102756 [TBL] [Abstract][Full Text] [Related]
7. Reduction and Scavenging of Chemically Reactive Drug Metabolites by NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 and Variability in Hepatic Concentrations. den Braver-Sewradj SP; den Braver MW; Toorneman RM; van Leeuwen S; Zhang Y; Dekker SJ; Vermeulen NPE; Commandeur JNM; Vos JC Chem Res Toxicol; 2018 Feb; 31(2):116-126. PubMed ID: 29281794 [TBL] [Abstract][Full Text] [Related]
9. Effects of 6-arylamino-5,8-quinolinediones and 6-chloro-7-arylamino-5,8-isoquinolinediones on NAD(P)H: quinone oxidoreductase (NQO1) activity and their cytotoxic potential. Ryu CK; Jeong HJ; Lee SK; You HJ; Choi KU; Shim JY; Heo YH; Lee CO Arch Pharm Res; 2001 Oct; 24(5):390-6. PubMed ID: 11693537 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of NAD(P)H:quinone oxidoreductase 1 (NQO1) and genomic gain of the NQO1 locus modulates breast cancer cell sensitivity to quinones. Glorieux C; Sandoval JM; Dejeans N; Ameye G; Poirel HA; Verrax J; Calderon PB Life Sci; 2016 Jan; 145():57-65. PubMed ID: 26687450 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of novel isothiazoloquinoline quinone analogues. Chen L; Xie YZ; Luo ZY; Liu LJ; Zou ZZ; Liu HD; Kong FR; Hao Y; Gao JL; Wang LL; Ma DY; Liu SY Bioorg Med Chem Lett; 2020 Aug; 30(16):127286. PubMed ID: 32631508 [TBL] [Abstract][Full Text] [Related]
12. Human NQO1 as a Selective Target for Anticancer Therapeutics and Tumor Imaging. Khan AEMA; Arutla V; Srivenugopal KS Cells; 2024 Jul; 13(15):. PubMed ID: 39120303 [TBL] [Abstract][Full Text] [Related]
13. NAD(P)H quinone oxidoreductase (NQO1): an enzyme which needs just enough mobility, in just the right places. Pey AL; Megarity CF; Timson DJ Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30518535 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological activity of 1,4-quinone moiety attached to betulin derivatives as potent DT-diaphorase substrate. Kadela-Tomanek M; Jastrzębska M; Marciniec K; Chrobak E; Bębenek E; Latocha M; Kuśmierz D; Boryczka S Bioorg Chem; 2021 Jan; 106():104478. PubMed ID: 33272711 [TBL] [Abstract][Full Text] [Related]
16. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Siegel D; Yan C; Ross D Biochem Pharmacol; 2012 Apr; 83(8):1033-40. PubMed ID: 22209713 [TBL] [Abstract][Full Text] [Related]
18. Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity. Beall HD; Winski S; Swann E; Hudnott AR; Cotterill AS; O'Sullivan N; Green SJ; Bien R; Siegel D; Ross D; Moody CJ J Med Chem; 1998 Nov; 41(24):4755-66. PubMed ID: 9822546 [TBL] [Abstract][Full Text] [Related]